Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2010

Open Access 01-12-2010 | SPECIAL ISSUE ARTICLE

Histone deacetylase inhibitors in Hodgkin lymphoma

Authors: Daniela Buglio, Anas Younes

Published in: Investigational New Drugs | Special Issue 1/2010

Login to get access

Summary

Although Hodgkin lymphoma (HL) is considered one of the most curable human cancers, the treatment of patients with relapsed and refractory disease, especially those who relapse after autologous stem cell transplantation, remains challenging. Furthermore, because of the young age of these patients, the impact of early mortality on the number of years lost from productive life is remarkable. Patients with relapsed HL post stem cell transplantation currently have no curative therapy, and are in need for new drugs and novel treatment strategies. While no new drugs have been approved for the treatment of patients with HL in more than three decades, several new agents are demonstrating promising results in early clinical trials. This review will focus on the emerging role of histone deacetylase inhibitors in patients with relapsed HL.
Literature
1.
2.
3.
4.
Baylin SB (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2(Suppl 1):S4–S11CrossRefPubMed
5.
Marsoni S, Damia G, Camboni G (2008) A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 3:164–171CrossRefPubMed
6.
Heider U, Kaiser M, Sterz J et al (2006) Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 76:42–50CrossRefPubMed
7.
Wang S, Yan-Neale Y, Cai R, Alimov I, Cohen D (2006) Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle 5:1662–1668CrossRefPubMed
8.
Brogdon JL, Xu Y, Szabo SJ et al (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109:1123–1130CrossRefPubMed
9.
Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784CrossRefPubMed
10.
Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51CrossRefPubMed
11.
Glozak MA, Sengupta N, Zhang X, Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15–23CrossRefPubMed
12.
Schrump DS (2009) Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 15:3947–3957CrossRefPubMed
13.
Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB (2009) HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 20:1293–1302CrossRefPubMed
14.
Duvic M, Talpur R, Ni X et al (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31–39CrossRefPubMed
15.
Piekarz RL, Frye R, Turner M et al (2009) Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27:5410–5417CrossRefPubMed
16.
Khan N, Jeffers M, Kumar S et al (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409:581–589CrossRefPubMed
17.
Bi G, Jiang G (2006) The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 3:285–290PubMed
18.
Beumer JH, Tawbi H (2010) Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol 5(3):196-208
19.
Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27:5459–5468CrossRefPubMed
20.
Borbone E, Berlingieri MT, De Bellis F et al (2010) Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 29:105–116
21.
Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958–3969CrossRefPubMed
22.
Marks PA, Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107:600–608CrossRefPubMed
23.
O’Connor OA, Heaney ML, Schwartz L et al (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166–173CrossRefPubMed
24.
Kirschbaum MH, Goldman BH, Zain JM et al (2007) Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory hodgkin lymphoma: SWOG 0517. Blood (ASH Annual Meeting Abstracts) 110:2574
25.
Kirschbaum MH, Zain JM, Popplewell L et al (2007) A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent Non Hodgkin Lymphoma. A California Cancer Consortium Study. Blood (ASH Annual Meeting Abstracts) 110:2568
26.
Younes A, Pro B, Fanale M et al (2007) Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin Lymphoma (HL). Blood (ASH Annual Meeting Abstracts) 110:2566
27.
Younes A, Wedgwood A, McLaughlin P et al (2007) Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. Blood (ASH Annual Meeting Abstracts) 110:2571
28.
Younes A (2009) Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology 2009:507–519
29.
Dickinson M, Ritchie D, DeAngelo DJ et al (2009) Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 147:97–101CrossRefPubMed
30.
Schwering I, Brauninger A, Klein U et al (2003) Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101:1505–1512CrossRefPubMed
31.
Ushmorov A, Ritz O, Hummel M et al (2004) Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 104:3326–3334CrossRefPubMed
32.
Ushmorov A, Leithauser F, Sakk O et al (2006) Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 107:2493–2500CrossRefPubMed
33.
Khaskhely NM, Buglio D, Shafer J, Bollard CM, Younes A (2009) The Histone Deacetylase (HDAC) Inhibitor Entinostat (SNDX-275) targets Hodgkin Lymphoma through a dual mechanism of immune modulation and apoptosis induction. Blood (ASH Annual Meeting Abstracts) 114:1562
34.
Buglio D, Mamidipudi V, Khaskhely NM et al (2009) The histone deacetylase inhibitor MGCD0103 down regulates CD30, activates NF-Kb, and synergizes with proteasome inhibitors by HDAC6 independent mechanism in Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:3735
35.
Buglio D, Georgiakis GV, Hanabuchi S et al (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112:1424–1433CrossRefPubMed
36.
Bollard CM, Aguilar L, Straathof KC et al (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease. J Exp Med 200:1623–1633CrossRefPubMed
37.
Bollard CM, Gottschalk S, Leen AM et al (2007) Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110:2838–2845CrossRefPubMed
38.
Israel BF, Kenney SC (2003) Virally targeted therapies for EBV-associated malignancies. Oncogene 22:5122–5130CrossRefPubMed
39.
Feng WH, Hong G, Delecluse HJ, Kenney SC (2004) Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 78:1893–1902CrossRefPubMed
40.
Feng WH, Kenney SC (2006) Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 66:8762–8769CrossRefPubMed
41.
Chambost H, Van Baren N, Brasseur F et al (2000) Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood 95:3530–3533PubMed
42.
Colleoni GW, Capodieci P, Tickoo S, Cossman J, Filippa DA, Ladanyi M (2002) Expression of SSX genes in the neoplastic cells of Hodgkin’s lymphoma. Hum Pathol 33:496–502CrossRefPubMed
43.
Shichijo S, Yamada A, Sagawa K et al (1996) Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2′-deoxycytidine. Jpn J Cancer Res 87:751–756PubMed
44.
Gloghini A, Buglio D, Khaskhely NM et al (2009) Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br J Haematol 147:515–525CrossRefPubMed
45.
Buglio D, Georgakis GV, Hanabuchi S et al (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112:1424–1433CrossRefPubMed
46.
Fournel M, Bonfils C, Hou Y et al (2008) MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7:759–768CrossRefPubMed
47.
Martell RE, Garcia-Manero G, Younes A et al (2009) Clinical development of MGCD0103, an isotype-selective HDAC inhibitor: pericarditis/pericardial effusion in the context of overall safety and efficacy. Blood (ASH Annual Meeting Abstracts) 114:4756
48.
Younes A, Ong T-C, Ribrag V et al (2009) Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin Lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant. Blood (ASH Annual Meeting Abstracts) 114:923
49.
Viviani S, Bonfante V, Fasola C, Valagussa P, Gianni AM (2008) Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin’s lymphoma patients. J Clin Oncol 26:2008 (May suppl; abstract 8532)
50.
Carlo-Stella C, Guidetti A, Viviani S et al (2008) Phase II trial of combination of the histone deacetylase inhibitor ITF2357 and meclorethamine demonstrates clinical activity and safety in heavily pretreated patients with relapsed/refractory Hodgkin Lymphoma (HL). Blood (ASH Annual Meeting Abstracts) 112:2586
51.
Spencer A, DeAngelo DJ, Prince HM et al (2008) Oral panobinostat (LBH589), a novel deacetylase inhibitor (DACi) demonstrates clinical activity in relapsed/refractory Hodgkin lymphoma (HL). Ann Oncol 19:136, AbstractCrossRef
Metadata
Title
Histone deacetylase inhibitors in Hodgkin lymphoma
Authors
Daniela Buglio
Anas Younes
Publication date
01-12-2010
Publisher
Springer US
Published in
Investigational New Drugs / Issue Special Issue 1/2010
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9588-y

Other articles of this Special Issue 1/2010

Investigational New Drugs 1/2010 Go to the issue

SPECIAL ISSUE ARTICLE

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies

SPECIAL ISSUE ARTICLE

The DAC system and associations with multiple myeloma

SPECIAL ISSUE ARTICLE

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

SPECIAL ISSUE ARTICLE

Deactylase inhibition in myeloproliferative neoplasms

SPECIAL ISSUE ARTICLE

The DAC system and associations with acute leukemias and myelodysplastic syndromes

SPECIAL ISSUE ARTICLE

The deacetylase inhibitors—here to stay!
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits